Citadel Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19M | Sell |
36,300
-6,800
| -16% | -$3.25M | ﹤0.01% | 2394 |
|
|
2025
Q4 | $25.1M | Sell |
43,100
-16,700
| -28% | -$8.53M | ﹤0.01% | 2112 |
|
|
2025
Q3 | $27.4M | Buy |
59,800
+4,400
| +8% | +$1.64M | ﹤0.01% | 1962 |
|
|
2025
Q2 | $16.8M | Buy |
55,400
+18,300
| +49% | +$5.45M | ﹤0.01% | 2368 |
|
|
2025
Q1 | $12.3M | Sell |
37,100
-38,300
| -51% | -$12.6M | ﹤0.01% | 2595 |
|
|
2024
Q4 | $23.3M | Sell |
75,400
-2,600
| -3% | -$731K | ﹤0.01% | 2016 |
|
|
2024
Q3 | $16.6M | Buy |
78,000
+5,700
| +8% | +$1.46M | ﹤0.01% | 2267 |
|
|
2024
Q2 | $20.3M | Sell |
72,300
-9,700
| -12% | -$2.31M | ﹤0.01% | 1989 |
|
|
2024
Q1 | $21.9M | Buy |
82,000
+31,300
| +62% | +$7.38M | ﹤0.01% | 1975 |
|
|
2023
Q4 | $11.7M | Buy |
50,700
+11,400
| +29% | +$1.99M | ﹤0.01% | 2636 |
|
|
2023
Q3 | $5.74M | Sell |
39,300
-12,200
| -24% | -$2.3M | ﹤0.01% | 3441 |
|
|
2023
Q2 | $11.9M | Sell |
51,500
-27,000
| -34% | -$7.31M | ﹤0.01% | 2453 |
|
|
2023
Q1 | $19M | Sell |
78,500
-90,700
| -54% | -$24.7M | ﹤0.01% | 1973 |
|
|
2022
Q4 | $49.1M | Buy |
169,200
+136,900
| +424% | +$13.4M | 0.01% | 1135 |
|
|
2022
Q3 | $2.1M | Sell |
32,300
-2,900
| -8% | -$201K | ﹤0.01% | 5500 |
|
|
2022
Q2 | $2.52M | Sell |
35,200
-25,200
| -42% | -$1.85M | ﹤0.01% | 5084 |
|
|
2022
Q1 | $5.93M | Buy |
60,400
+10,300
| +21% | +$868K | ﹤0.01% | 3850 |
|
|
2021
Q4 | $4.25M | Buy |
50,100
+18,700
| +60% | +$1.54M | ﹤0.01% | 4627 |
|
|
2021
Q3 | $2.5M | Buy |
31,400
+8,300
| +36% | +$717K | ﹤0.01% | 5799 |
|
|
2021
Q2 | $2.25M | Buy |
23,100
+13,700
| +146% | +$1.62M | ﹤0.01% | 6304 |
|
|
2021
Q1 | $1.1M | Buy |
9,400
+2,700
| +40% | +$315K | ﹤0.01% | 7878 |
|
|
2020
Q4 | $745K | Sell |
6,700
-3,000
| -31% | -$367K | ﹤0.01% | 7395 |
|
|
2020
Q3 | $1.15M | Sell |
9,700
-900
| -8% | -$97.7K | ﹤0.01% | 5774 |
|
|
2020
Q2 | $1.2M | Buy |
10,600
+5,800
| +121% | +$570K | ﹤0.01% | 5490 |
|
|
2020
Q1 | $320K | Sell |
4,800
-6,800
| -59% | -$567K | ﹤0.01% | 7216 |
|
|
2019
Q4 | $1.06M | Sell |
11,600
-21,000
| -64% | -$2.04M | ﹤0.01% | 5488 |
|
|
2019
Q3 | $2.81M | Buy |
32,600
+4,200
| +15% | +$394K | ﹤0.01% | 3950 |
|
|
2019
Q2 | $2.98M | Buy |
28,400
+4,500
| +19% | +$482K | ﹤0.01% | 3868 |
|
|
2019
Q1 | $2.99M | Sell |
23,900
-4,600
| -16% | -$572K | ﹤0.01% | 3765 |
|
|
2018
Q4 | $3.21M | Buy |
28,500
+8,500
| +43% | +$1.32M | ﹤0.01% | 3418 |
|
|
2018
Q3 | $4.28M | Buy |
20,000
+16,000
| +400% | +$4.01M | ﹤0.01% | 3195 |
|
|
2018
Q2 | $1.12M | Buy |
+4,000
| New | +$702K | ﹤0.01% | 5017 |
|
|
2016
Q1 | – | Sell |
-1,011
| Closed | -$12K | – | 7477 |
|
|
2015
Q4 | $12K | Buy |
1,011
+437
| +76% | +$12K | ﹤0.01% | 8208 |
|
|
2015
Q3 | $35K | Sell |
574
-103
| -15% | -$7.43K | ﹤0.01% | 7817 |
|
|
2015
Q2 | $53K | Buy |
677
+86
| +15% | +$7.22K | ﹤0.01% | 7610 |
|
|
2015
Q1 | $40K | Buy |
591
+2
| +0.3% | +$172 | ﹤0.01% | 7528 |
|
|
2014
Q4 | $55K | Sell |
589
-42
| -7% | -$4.34K | ﹤0.01% | 7123 |
|
|
2014
Q3 | $67K | Buy |
631
+77
| +14% | +$10.7K | ﹤0.01% | 6701 |
|
|
2014
Q2 | $79K | Buy |
554
+131
| +31% | +$19.1K | ﹤0.01% | 6411 |
|
|
2014
Q1 | $64K | Sell |
423
-308
| -42% | -$60.7K | ﹤0.01% | 6568 |
|
|
2013
Q4 | $134K | Buy |
731
+225
| +44% | +$41.2K | ﹤0.01% | 5379 |
|
|
2013
Q3 | $112K | Sell |
506
-1,540
| -75% | -$328K | ﹤0.01% | 5266 |
|
|
2013
Q2 | $357K | Buy |
+2,046
| New | +$533K | ﹤0.01% | 4146 |
|
Other funds holding MDGL
BBA
RI
ACA
PC
VPM
VCM
Citadel Advisors's MDGL Position: Q1 2026 in Review
Citadel Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 1,156% in Q1 2026, buying an estimated $200M and bringing the position to 453,843 shares worth $238M. The position accounts for 0.04% of the portfolio, ranked #381.
Citadel Advisors first reported a position in MDGL in Q2 2013 and has held it in 48 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.
- Citadel Advisors held 453,843 shares of Madrigal Pharmaceuticals worth $238M as of Q1 2026.
- Citadel Advisors bought 417,709 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $200M.
- Madrigal Pharmaceuticals made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #381 holding.
- Citadel Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
- 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.